Outcomes of Liposomal Irinotecan With 5‐FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status
Liposomal irinotecan plus 5-FU/LV regimen is a feasible second-line treatment option for PDAC patients with borderline performance status, with a safety profile consistent with clinical trial findings.
Authors
- Chieh-Ying Chang (ORCID: https://orcid.org/0009-0004-0598-5483)
- Wen-Chi Chou
- Jen-Shi Chen
- Tai-Jan Chiu
- Yen‐Yang Chen
Institutions
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Linkou Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Cancer Diagnosis & Prognosis
- Published
- 2025-03-01
- DOI
- https://doi.org/10.21873/cdp.10430
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05